A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...

New research from the University of St Andrews, the University of Copenhagen and Drexel University has developed AI ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production ...

A newly published study says that the body’s own immune system may be responsible for driving the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease. Scientists ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

Add Yahoo as a preferred source to see more of our stories on Google. Eric Dane is opening up and being completely vulnerable with fans in his first video addressing his ALS diagnosis and a new ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in an early study.

The drug targets a specific mutation that applies to only 2% of ALS patients.